DKP Genomics, LLC

Alpha Genesis® Inc. (AGI) provides the highest quality nonhuman primate products and bio-research services world-wide, with a customer base that extends across North America, Europe, and Asia. The Alpha Genesis Primate Research Center is a full-service facility that offers Nonhuman Primates for Biomedical Research, Contract Research and Consultation, Primate Housing and CDC Quarantine, and Biological Products and Materials. AGI maintains 100+ acres of primate breeding and holding facilities, and our large inventory of monkeys allows us to best serve your primate research needs. All AGI monkeys are of optimal health and are readily accessible for immediate availability and use. Individual monkey health records available to prospective clients upon request.

Principal research areas currently include: Aging and Metabolic Diseases, Immunogenetics and Immonology, Reproduction, Neurobiology, Physiological Ethology, Psychobiology. Recent research focus: embryonic stem cells, AIDS vaccine research, women's health, developmental disorders, glaucoma and presbyopia, osteoporosis, Parkinson's, movement disorders, diabetes, drug addiction, and obesity.

Veterinary training is available in primate biology, medicine, biomedical research, and behavior. Unique opportunity to work directly with monkeys. Educational opportunities are available to students case-by-case. Interested students should submit a research plan to info@alphagenesisinc.com. Outreach activities are also considered.

Since its inception AGI has grown to serve a broader customer base as we have strengthened our dedication to providing the very best and most cost-effective research and development support to the scientific community. Each AGI employee that works within our AAALAC accredited facilities is highly qualified and carefully trained specifically to complete the job you hired us to do.

If you have questions or would like to place an order, please e-mail AGI at info@alphagenesisinc.com or call toll-free 866.789.MONK (6665). Visit us on the web at www.alphagenesisinc.com or at www.primateresearch.com

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.

Fractyl Health is a leader in creating innovative therapies to address the root cause of type 2 diabetes.

We were founded based on groundbreaking research and biological insights showing the key role of the intestine in metabolic control. Our therapies are uniquely designed to target and control this controller for the treatment of metabolic disease.

Our lead program, Revita DMR, is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes.

Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease.

Fractyl is located in Lexington, Mass.

Opened in 1986, Robarts Research Institute is a non-profit medical research facility in London, Ontario, with more than 600 people working to investigate some of the most debilitating diseases of our time, from heart disease and stroke to diabetes, Alzheimer’s and many forms of cancer.

From our roots under the scientific leadership of renowned neurologist Dr. Henry Barnett - whose work with Aspirin as a preventive therapy for heart attack and stroke remains one of the most important developments in 20th century medicine - the Institute has applied that formula and become a national leader in biological, clinical and imaging research.

Some quick facts about Robarts:

* Key strengths in advanced medical imaging, cellular and molecular biology, genomics, immunology and stem cell biology.
* Interdisciplinary approach unique in Canada with physicians and physicists, biologists and biomedical engineers, all working under one roof with collaborations extending to 20 countries worldwide.
* State-of-the-art building expansion - officially opened in 2003 - doubling space available for research to nearly 200,000 sq. ft.
* Commercialization success with more than 80 patents filed, 15 licensing agreements, eight spinoff companies that have raised more than $45 million in investment capital.

RiboWiz Scientific is a digital biotechnology company integrating both A.I. software and life science. RiboWiz offers customized service and cloud-based subscription licensing to accurately predict and maximize recombinant protein production for life science companies using proprietary RiboScan™ software platform.

Creating high-value recombinant proteins, e.g. biologics, enzymes, vaccines, antibodies, and pesticides, is important to life science companies across a broad range of industrial applications. For example, proteins can be over-expressed for use in basic research, used as insecticides, or used as targets for small molecule drugs or antibodies for the treatments of AIDS, diabetes, cancer and other diseases.

Many R&D projects are stymied by conventional protein expression methods that require multiple trial-and-error laboratory testing to produce proteins at the desired level. RiboScan™ provides more of the desired protein candidates with fewer folding errors and protein aggregations by simulating and modulating ribosomal speed and accuracy during protein synthesis.

Unlike current alternatives that require synthesis and laboratory testing of hundreds of genes construct, RiboScan™ accurately predicts protein expression levels and designs an optimized gene construct with minimal subsequent laboratory testing. This significantly accelerates clients’ R&D projects, reduces costs, expedites innovations, and enhances protein quality to make clients more competitive in bringing multiple novel compounds to market faster.

RiboWiz’s mission is to help clients successfully produce high-value, difficult-to-make recombinant proteins faster for new treatments of diseases and also for the advancement of medicine and biotechnology.